Prof. Harry L.A. Janssen, MD PhD
Professor of Hepatology

Postal address:
Department of Gastroenterology and Hepatology, Erasmus MC, 's Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands

Contact details:
Send an email

Harry Janssen (1964) graduated from medical school at the Radboud University of Nijmegen, the Netherlands. During his study he spent one year as research fellow in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in chronic hepatitis B. He then trained in Internal Medicine at Leiden University Medical Center and in Gastroenterology & Hepatology at Rotterdam Erasmus University Medical Center. Following his registration as Gastroenterologist he returned to the Mayo Clinic for a research fellowship in Hepatology at the Center of Basic Research in Digestive Diseases. In 2001 he became a staff member and in 2006 he was appointed as full professor of Hepatology and chief of the Section Liver Diseases and Transplantation in Rotterdam.
As principle investigator prof. Janssen coordinated numerous European and global multicenter studies on antiviral treatment for chronic viral hepatitis. He was awarded a Clinical Fellowship and an Innovational Research grant (VIDI) from the Netherlands Organisation of Scientific Research (NWO) to study strategies of immune control in viral hepatitis and published many international articles on this subject. Professor Janssen is chairman of the Dutch Association of Hepatology and was elected as Rising Star in Gastroenterology and Hepatology by the Association of the National European Societies of Gastroenterology. He has been member of the editorial board of Hepatology, Journal of Hepatology and Best Practice in Gastroenterology. He has published over 200 original peer-reviewed papers. In addition to his longstanding expertise in antiviral therapy of chronic viral hepatitis, professor Janssen is a leading scientist in the field of vascular disorders of the liver.

Selected references:

• Janssen HLA, Zonneveld van M, Senturk H, Zeuzem S, Akarca U, Cakaloglu Y, Simon K, So Man Kit T, Gerken G, Man de RA, Niesters HG, Zondervan P, Schalm SW (2005)
  Pegylated interferon a-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
  Lancet 365, 123-129. [Abstract/Full Text]
• Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HLA
  for the European Network for Vascular Disorders of the Liver (EN-Vie). Risk Factors, Management and Outcome of Budd-Chiari Syndrome.
  Annals of Internal Medicine, 2009;151:167-75. [Abstract/Full Text]
• Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns M, Hansen BE, Schalm SW, Janssen HLA(2007)
  Sustained virological response leads to an improved clinical outcome in patients with hepatitis C and advanced fibrosis.
  Annals of Internal Medicine 147,677-684.[Abstract/Full Text]
• Buster EH, Flink HJ, Cadaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL(2008)
  Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon alpha-2b
  Gastroenterol 2008, in press.[Abstract/Full Text]
• Reijnders JGP, Perquin MJ, Zhang N, Hansen BE, Janssen HLA.
  Nucleos(t)ide analogues induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
  Gastroenterology 2010;139:491-8. [Abstract/Full Text]

  
  

Do a PubMed search for references by Harry Janssen.

Back